NicOx

Quality 0.50 · 4 views · Updated 2 months ago

title: "NicOx" type: doc version: 1 created: 2026-02-28 author: "Wikipedia contributors" status: active scope: public tags: ["pharmaceutical-companies-of-france", "companies-based-in-provence-alpes-côte-d'azur", "companies-listed-on-euronext-paris", "french-companies-established-in-1996"] topic_path: "geography/france" source: "https://en.wikipedia.org/wiki/NicOx" license: "CC BY-SA 4.0" wikipedia_page_id: 0 wikipedia_revision_id: 0

::data[format=table title="Infobox company"]

Field	Value
name	Nicox S.A.
logo	NicOx logo.svg
type	Société Anonyme
traded_as
Euronext Growth
foundation
location_city	Sophia Antipolis
location_country	France
homepage
::

Nicox S.A. is a French ophthalmology company developing treatments to maintain vision and improve ocular health. Nicox is headquartered in Sophia Antipolis, France, and its Chairman and CEO is Michele Garufi.

Nicox is listed on Euronext Paris (Compartment B: Mid-Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes. Its pipeline includes three programs in development, and it has two U.S. Food and Drug Administration (FDA) approved products.

Pipeline

Nicox's lead program in clinical development is NCX 470, a novel, second-generation nitric oxide-donating bimatoprost analog, for lowering intraocular pressure (IOP) in patients with glaucoma. NCX 470 is designed to release both bimatoprost, which is marketed under the brand name LUMIGAN, and nitric oxide following instillation into the eye. Bimatoprost is a prostaglandin analog, the most widely used class of drugs for IOP lowering in patients with open angle glaucoma and ocular hypertension.

The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis. Nicox generates revenue from VYZULTA(R) in glaucoma and ZERVIATE(TM), or cetirizine ophthalmic solution, in allergic conjunctivitis. It has ongoing partnerships with Bausch & Lomb, Kowa, Eyevance Pharmaceuticals and Ocumension Therapeutics.

Agreement with Ocumension

In 2019, Nicox and Ocumension Therapeutics signed an agreement to allow Ocumension the rights to develop and commercialize Zerviate, a cetirizine ophthalmic solution, for the Chinese and South East Asian markets. The deal would see Nicox eligible for up to $17.2 million, along with tiered royalties of between 5 and 9% of the net sales. In July 2021 the deal was amended and Ocumension paid $2 million to Nicox as an advance payment of future development and regulatory milestones.

References

"COX: Nicox Stock Price Quote - EN Paris - Bloomberg".
"Here's a French Biotech Investors May Not Care About Enough". Bloomberg.com.
"Michele Garufi, PDG de NicOx".
"NICOX {{!}} FR0013018124 {{!}} Euronext exchange Live quotes".
"Nicox S.A. (NICXF) Stock Price Today, Quote & News | Seeking Alpha".
{{ClinicalTrialsGov. NCT03657797. Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension
(2014). "Glaucoma management: relative value and place in therapy of available drug treatments". Therapeutic Advances in Chronic Disease.
"Prostaglandin analogs: The "gold standard" for glaucoma".
{{ClinicalTrialsGov. NCT03926026. Study Evaluating the Safety and Tolerability of NCX 4251 for the Treatment of Acute Exacerbations of Blepharitis
(31 March 2020). "NICOX: Nicox Announces ZERVIATE Launch by Partner Eyevance Pharmaceuticals in the United States". Bloomberg.com.
(11 March 2020). "BRIEF-Nicox Updates Agreement with Ocumension Therapeutics on ZERVIATE". Reuters.
NICOX. (2021-07-05). "Nicox to Receive $2 Million from Ocumension Therapeutics as Advance Milestone Payment under ZERVIATE® Agreement".

::callout[type=info title="Wikipedia Source"] This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page. ::